Assessment of high-risk human papillomavirus infections and associated cervical dysplasia in HIV-positive pregnant women in Germany: a prospective cross-sectional two-centre study
- PMID: 36576558
- DOI: 10.1007/s00404-022-06890-w
Assessment of high-risk human papillomavirus infections and associated cervical dysplasia in HIV-positive pregnant women in Germany: a prospective cross-sectional two-centre study
Abstract
Purpose: Invasive cervical cancer (ICC) is associated in nearly 100% with persistent high-risk Human Papillomavirus (HR-HPV) infection. ICC is still one of the leading causes for cancer mortality in women worldwide. The immunosuppressive influence of Human Immunodeficiency Virus (HIV) and the immunocompromised period of pregnancy due to tolerance induction against the hemiallogeneic fetus, are generally risk factors for acquisition and persistence of HR-HPV infections and their progression to precancerous lesions and HPV-associated carcinoma.
Methods: Overall, 81 pregnant women living with HIV (WLWH) were included. A medical history questionnaire was used to record clinical and HIV data. Participants received cervicovaginal cytological smear, colposcopy and HPV testing. HPV test was performed using BSGP5+/6+ PCR with Luminex read-out. The HR-HPV genotypes 16, 18, 31, 33, 45, 52, 58 were additionally grouped together as high-high-risk HPV (HHR-HPV) for the purpose of risk-adapted analysis.
Results: HR-HPV prevalence was 45.7%. Multiple HPV infections were detected in 27.2% of participants, of whom all had at least one HR-HPV genotype included. HR-HPV16 and HR-HPV52 were the most prevalent genotypes and found when high squamous intraepithelial lesion (HSIL) was detected by cytology. HIV viral load of ≥ 50 copies/ml was associated with higher prevalence of HR-HPV infections. Whereas, CD4 T cells < 350/µl showed association with occurrence of multiple HPV infections. Time since HIV diagnosis seemed to impact HPV prevalence.
Conclusion: Pregnant WLWH require particularly attentive and extended HPV-, colposcopical- and cytological screening, whereby clinical and HIV-related risk factors should be taken into account.
Keywords: Cancer prevention; Human immunodeficiency virus; Human papillomavirus; Pregnancy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study.Int J Gynecol Cancer. 2022 Jun 6;32(6):716-723. doi: 10.1136/ijgc-2021-003327. Int J Gynecol Cancer. 2022. PMID: 35354606
-
Human Papillomavirus infection and cervical lesions in HIV infected women on antiretroviral treatment in Thailand.J Infect. 2017 May;74(5):501-511. doi: 10.1016/j.jinf.2017.02.007. Epub 2017 Feb 28. J Infect. 2017. PMID: 28254419
-
High burden of human papillomavirus and premalignant cervical lesions among women starting HIV treatment in KwaZulu-Natal, South Africa.Sex Transm Infect. 2025 Apr 15;101(3):187-190. doi: 10.1136/sextrans-2024-056129. Sex Transm Infect. 2025. PMID: 39557497 Free PMC article.
-
Human papillomavirus prevalence in pregnant women living with human immunodeficiency virus infection: a scoping review of the literature.J Perinat Med. 2023 Aug 7;52(1):1-13. doi: 10.1515/jpm-2023-0221. Print 2024 Jan 29. J Perinat Med. 2023. PMID: 37540166
-
The recent natural history of human papillomavirus cervical infection in women living with HIV: A scoping review of meta-analyses and systematic reviews and the construction of a hypothetical model.HIV Med. 2023 Aug;24(8):877-892. doi: 10.1111/hiv.13490. Epub 2023 Apr 16. HIV Med. 2023. PMID: 37062862
Cited by
-
Impact of HIV infection on cervical intraepithelial neoplasia detection in pregnant and non-pregnant women in Germany: a cross-sectional study.Arch Gynecol Obstet. 2024 Dec;310(6):3099-3110. doi: 10.1007/s00404-024-07813-7. Epub 2024 Nov 7. Arch Gynecol Obstet. 2024. PMID: 39508903
-
Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies.Mol Ther. 2024 Jul 3;32(7):2340-2356. doi: 10.1016/j.ymthe.2024.04.036. Epub 2024 May 6. Mol Ther. 2024. PMID: 38715363 Free PMC article.
References
-
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH431%3... - DOI - PubMed
-
- World Health Organisation (WHO) (2021) WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV). WHO Publishing. https://www.who.int/publications/i/item/9789240040434 . Accessed 28 June 2022
-
- Chesson HW, Dunne EF, Hariri S, Markowitz LE (2014) The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 41(11):660–664. https://doi.org/10.1097/OLQ.0000000000000193 - DOI - PubMed - PMC
-
- Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT et al (2012) Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30(Suppl 5):F24-33. https://doi.org/10.1016/j.vaccine.2012.05.089 - DOI - PubMed - PMC
-
- Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S et al (2011) Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20(4):699–707. https://doi.org/10.1158/1055-9965.EPI-10-1108 - DOI - PubMed
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials